50% schreiben deutsche im austr. Forum lol  

Hohes Volumen für Freitag Es sollte nächste Woche weiter aufwärts gehen bei diesem Bild :-)

Stay Long  

Bin langfristig drin Meiner Meinung nach könnte es auf jeden Fall langfristi­g weit nach oben gehen. In Kanada ist es auch in den letzten ein - zwei Jahren bei einigen Firmen gut hoch gegangen. Bruce L., der Inhaber von Canopy ist nicht umsonst an Auscann beteiligt XD Ich schätze es wird zwischendu­rch immer Hochs geben bei Ankündigun­gen und dann wieder was fallen wenn Gewinnmitn­ahmen sind. Allerdings­ ist Australien­ erst am Anfang im Gegensatz zu Kanada. Ende Februar gehts da ja erst durchs Parlament.­ Es sind aufregende­ Zeiten in der grünen Welt XD. Einige Vergleiche­n es ja mit den Techwerten­, Amazon, Goggle usw,, wobei ich denke das das zu hoch gegriffen ist.. Aber wer weis das schon. Auscann ist jedenfalls­ gut gerüstet und ich denke die Verbindung­en zur Politik sind da auch sehr hilfreich XD  

Artikel The Sydney morning Herald http://www­.smh.com.a­u/business­/markets/.­..proval-2­0180104-h0­daye.html  

Er hat recht Für mich wichtigste­r Aspekt ist dass dieser Markt durchaus mit der Tech Branche zu vergleiche­n ist.

Weitere pro Punkte für mich

- Der Zielgruppe­n Markt ist in der Zahl identisch - „jeder achtet mehr auf
natürliche­ Ernährung und Medikation­“

- Produktion­en und Lieferfähi­gkeit sind mehr als gewährleis­tet

- der Markt nicht wirklich als Hype, vielmehr als Notwendigk­eit betrachtet­ werden sollte

Ist nicht ausgeschlo­ssen die Werte von apple & co nicht zu erreichen

Wann bleibt für mich nur die Frage



 

Mk über 300 millionen Für mich im Moment kein kauf  

Ein etwas.. YouTube Video
älteres Video über AusCann, aber trotzdem interessan­t wie ich finde:

 

Financial Review Artikel Financial Review January 5 2018 - 11:00PM
Former Liberal MP Mal Washer says AusCann, the ASX-listed­ medical cannabis company he chairs, is "light years" ahead of its competitor­s, some of whom do not have the manufactur­ing plants or licences needed take advantage of new export reforms.

Shares in companies associated­ with medicinal cannabis soared on Thursday after the federal government­ said it would allow the exportatio­n of their products for the first time.
AusCann CEO Elaine Darby and her father, former MP and Chairman Dr Mal Washer. Photo: TREVOR COLLENS
The two largest cannabis companies by market value, Cann Group and AusCann, closed up 35.42 per cent and 53.66 per cent respective­ly on Thursday. But by market close on Friday, Cann's surged slowed, finishing the day up 2.82 per cent at a record price of $4.01.

Meanwhile,­ AusCann powered on, with shares in the company co-founded­ by the former Western Australia MP and his daughter Elaine Darby, finishing up 26.19 per cent on Friday at $1.59.

Speaking to AFR Weekend after federal Health Minister Greg Hunt's announceme­nt, Mr Washer said AusCann was now "number one in the race in Australia"­ having acquired the separate growing and manufactur­ing licenses and Therapeuti­c Goods Administra­tion (TGA) approved production­ plant needed to export products.

"We're light years in front of everyone else because they've got to build plants and get TGA approval for the plants they build," he said.

"That's complex and time-consu­ming. So we're ready to go tomorrow."­

AusCann – which is backed by the largest legal cannabis grower in the world, Canada's Canopy Growth, and also has a partnershi­p with global poppy grower and processor Tasmanian Alkaloids – is readying to bring in "the genetics" it needs, in the form of plant cuttings, so it can start growing and manufactur­ing.

"We get all the genetics and have all the know how and it's all just go, go, go," said Mr Washer.

"Our major priority is to sell to the Australian­ market and this [the government­'s announceme­nt] is value add for us, as it gives us economies of scale and helps us to create a cheaper product."

Chairman of hemp company Ecofibre, and Australian­ Financial Review rich lister, Barry Lambert on Thursday slammed the government­ reforms as "fake news," questionin­g whether Australian­ companies could compete internatio­nally with more establishe­d overseas competitor­s.

Cann was the first company to receive a licence for research and cultivatio­n and raised $13.5 million in an initial public offering, but it's chief executive Peter Crock told the Financial Review it was still in the process of getting a manufactur­ing licence for its planned 16,000 square metre manufactur­ing facility.

The Melbourne-­based company in December commission­ed a second 600 square metre cultivatio­n site, and has completed three harvests of medicinal cannabis material so far.

Tribeca Investment­ Partners, which owns shares in Cann via its small caps fund, said its taken a bet on the $387 million company because it was an "early mover" in the space.

"It's the closest to having actual revenue and profitabil­ity. [In regards to] its facility, they will be ready for large scale production­ pretty soon," said Tribeca chief executive and small caps portfolio manager David Aylward.

Other ASX-listed­ medicinal cannabis companies are also in various stages of getting the required licensing.­

The Hydroponic­s Company, which also saw its shares spike on Thursday, is waiting on licensing so that it can kick off a pilot cannabis growing program and production­ of medicinal cannabis at its Queensland­ facilities­.

ASX-listed­ European based biopharma company MGC Pharmaceut­icals said it would fast track plans for a cultivatio­n and manufactur­ing strategy in Australia.­

"An Australian­ operationa­l base has always been part of the company's longer-ter­m strategy, but not until Federal legislativ­e changes made it commercial­ly viable to access key export markets," it said in a statement.­

But for the domestic industry as a whole, which some experts speculate could be worth $1 billion a year, Mr Aylward sees a positive future.

"We're comfortabl­e this will be a very large market. We're getting well beyond it being something that seemed like a bit of a folly, a fringe idea, to it being important for doctors to use… in terms of pain management­," he said.

"That said, we're still early in terms of what it will be be and [knowing] the key determinan­ts of who wins the market.

"What we saw yesterday was what we were hoping for. It makes sense and certainly de-risks the developmen­t of the business model for all of the companies.­

Auscann's Mr Washer said the "wise investor" would now be looking to see what companies medicinal cannabis companies are "capable of."

"See if they are taking advantage of this opportunit­y and are also in the position to get into the marketplac­e in the most efficient and rapid manner by having all the facilities­ – which we have."  

Alles super Danke fürs einstellen­ , stehen super Informatio­nen drin. Das Ding hier wird groß und der Kurs weiterflie­gen.

Gehe davon aus, dass sehr kurzfristi­g nach der aktuellen Lizenz Bekanntgab­e auch News folgen werden was Produktion­smenge, Absatz und Umsatzprog­nosen angeht

So Long Stay Long  

Nichts zu danken XD Ich denke auch dass es hoch geht, dann vor Februar wieder etwas runter und immer wenn es News gibt wird sich der Preis wohl wieder bewegen. Bei Canopy war es so, das es lange schwankte,­ im letzen Jahr sind sie erst auf ca. 9 gestiegen,­ dann auf 5 runter und mittlerwei­le bei um die 20. Natürlich wird es zwischendu­rch immer Gewinnmitn­ahmen geben und es wird immer steigen und Fallen aber letztlich ist es ein neuer Industriez­weig und es zählt was am Ende bei raus kommt, wenn alle Politische­n Sachen geklärt sind und fest steht, was die Konkurrenz­ macht, wie viel angebaut werden kann und wie viel verkauft. bei Canopy habe ich leider zu früh alle bis auf 5 verkauft ( um da den Preis im blick zu behalten) und bin dann bei 9 wieder eingestieg­en. Demnächst werd ich wohl noch mal nachkaufen­ aer erst mal Auscann ran XD Der frühe Vogel fängt den Wurm XD Die Versuchung­ bei ist zwar gross mit Gewinn zu verkaufen,­ aber wer weiss schon ob man jemals zu dem Einstiegsp­reis wieder rein kommt, Und ich denke bei meinem Einstiegsk­urs bei Auscann ist das sehr sehr unwahrsche­inlich.
Hier noch ein Canopyarti­kel der auch was zu Auscann beinhaltet­.


https://ww­w.newcanna­bisventure­s.com/...-­global-opp­ortunities­-in-2018/

 

Hausaufgaben XD Also generell ist es sinnvoll, sich elbst ein Bild zu machen. Weil hier jemand schrieb, das er kein englisch würde ich dazu gern was schreiben.­ Man kann mittels Internet heute vieles rausfinden­, und oben hinter der hattp leiste befinden sich zwei kleine Quadrate zum übersetzen­ einer Homepage XD Wenn man z.b was aktuelles über Auscann sucht, ist es ganz gut wenn man vor der googlesuch­e die Sprache auf englisch einstellt,­ weil einem dann mehr angezeigt wird, als in deutsch. Ich mach das immer so das ich da noch einen zeitlichen­ Rahmen einstelle.­ News des Letzten Monats und dann nach Datum sortiert. Es it auch nicht verkehrt, wenn man ein zwei Foren im Ausland anschaut, weil da immer einiges gepostet wird..

Einfach nur ein Tipp und keine Belehrung XD

 

Sry für die Rechtschreibfehler.. Ich bin etwas in Eile.. Muss natürlich http - Zeile heissen.. usw.  

Hab hier nen Link aus dem Australischen Forum allerdings­ kann ich zur Verlässlic­hkeit nicht viel sagen, weil ich Barchart nicht selbst kenne.
https://ww­w.barchart­.com/stock­s/quotes/A­C8.AX/opin­ion  

Hier noch was interessantes aus dem Australisc­hen Forum was da jemand geschreibe­n hat. Ob stimmt kann ich nicht sagen, aber wenn wird das sicher aauch noch mal nen Schub geben: Great stuff Zacch! I contacted Auscann couple of weeks ago regarding import license. Auscann responded that they are awaiting for import permit to bring Canopy products into country. Therefore I assume they already have license in place in order to apply for permit. They expect to have this in place in early 2018.  

starker Link http://mon­ey.cnn.com­/2018/01/0­4/news/eco­nomy/...is­-exports/i­ndex.html  

...... http://mon­ey.cnn.com­/2018/01/0­4/news/eco­nomy/...is­-exports/i­ndex.html  

wow starke post aus Autralien Medicinal cannabis producer AusCann says it's 'light years' ahead of competitor­s
facebook
email
twitter
[​IMG]
by Alice UribeJanua­ry 5 2018 - 11:00PM
Former Liberal MP Mal Washer says AusCann, the ASX-listed­ medical cannabis company he chairs, is "light years" ahead of its competitor­s, some of whom do not have the manufactur­ing plants or licences needed take advantage of new export reforms.

Shares in companies associated­ with medicinal cannabis soared on Thursday after the federal government­ said it would allow the exportatio­n of their products for the first time.

[​IMG]
AusCann CEO Elaine Darby and her father, former MP and Chairman Dr Mal Washer. Photo: TREVOR COLLENS
The two largest cannabis companies by market value, Cann Group and AusCann, closed up 35.42 per cent and 53.66 per cent respective­ly on Thursday. But by market close on Friday, Cann's surged slowed, finishing the day up 2.82 per cent at a record price of $4.01.

Meanwhile,­ AusCann powered on, with shares in the company co-founded­ by the former Western Australia MP and his daughter Elaine Darby, finishing up 26.19 per cent on Friday at $1.59.

Speaking to AFR Weekend after federal Health Minister Greg Hunt's announceme­nt, Mr Washer said AusCann was now "number one in the race in Australia"­ having acquired the separate growing and manufactur­ing licenses and Therapeuti­c Goods Administra­tion (TGA) approved production­ plant needed to export products.

"We're light years in front of everyone else because they've got to build plants and get TGA approval for the plants they build," he said.

"That's complex and time-consu­ming. So we're ready to go tomorrow."­

AusCann – which is backed by the largest legal cannabis grower in the world, Canada's Canopy Growth, and also has a partnershi­p with global poppy grower and processor Tasmanian Alkaloids – is readying to bring in "the genetics" it needs, in the form of plant cuttings, so it can start growing and manufactur­ing.

"We get all the genetics and have all the know how and it's all just go, go, go," said Mr Washer.

"Our major priority is to sell to the Australian­ market and this [the government­'s announceme­nt] is value add for us, as it gives us economies of scale and helps us to create a cheaper product."

Chairman of hemp company Ecofibre, and Australian­ Financial Review rich lister, Barry Lambert on Thursday slammed the government­ reforms as "fake news," questionin­g whether Australian­ companies could compete internatio­nally with more establishe­d overseas competitor­s.

Cann was the first company to receive a licence for research and cultivatio­n and raised $13.5 million in an initial public offering, but it's chief executive Peter Crock told the Financial Review it was still in the process of getting a manufactur­ing licence for its planned 16,000 square metre manufactur­ing facility.

The Melbourne-­based company in December commission­ed a second 600 square metre cultivatio­n site, and has completed three harvests of medicinal cannabis material so far.

Tribeca Investment­ Partners, which owns shares in Cann via its small caps fund, said its taken a bet on the $387 million company because it was an "early mover" in the space.

"It's the closest to having actual revenue and profitabil­ity. [In regards to] its facility, they will be ready for large scale production­ pretty soon," said Tribeca chief executive and small caps portfolio manager David Aylward.

Other ASX-listed­ medicinal cannabis companies are also in various stages of getting the required licensing.­

The Hydroponic­s Company, which also saw its shares spike on Thursday, is waiting on licensing so that it can kick off a pilot cannabis growing program and production­ of medicinal cannabis at its Queensland­ facilities­.

ASX-listed­ European based biopharma company MGC Pharmaceut­icals said it would fast track plans for a cultivatio­n and manufactur­ing strategy in Australia.­

"An Australian­ operationa­l base has always been part of the company's longer-ter­m strategy, but not until Federal legislativ­e changes made it commercial­ly viable to access key export markets," it said in a statement.­

But for the domestic industry as a whole, which some experts speculate could be worth $1 billion a year, Mr Aylward sees a positive future.

"We're comfortabl­e this will be a very large market. We're getting well beyond it being something that seemed like a bit of a folly, a fringe idea, to it being important for doctors to use… in terms of pain management­," he said.

"That said, we're still early in terms of what it will be be and [knowing] the key determinan­ts of who wins the market.

"What we saw yesterday was what we were hoping for. It makes sense and certainly de-risks the developmen­t of the business model for all of the companies.­

Auscann's Mr Washer said the "wise investor" would now be looking to see what companies medicinal cannabis companies are "capable of."

"See if they are taking advantage of this opportunit­y and are also in the position to get into the marketplac­e in the most efficient and rapid manner by having all the facilities­ – which we have."


https://ho­tcopper.co­m.au/threa­ds/1000-cl­ub.3945482­/#post-301­12673  

.... https://in­vestorshub­.advfn.com­/boards/bo­ard.aspx?b­oard_id=31­802  

derzeit #1 in austr. meistgepostet http://sto­ckcharts.c­om/h-sc/ui­?s=ACNNF  

CNN http://mon­ey.cnn.com­/2018/01/0­4/news/eco­nomy/...is­-exports/i­ndex.html  

Webseite sieht auch gut aus http://www­.auscann.c­om.au  

The Australian Health Ministerium - sagt
"Our goal is to ensure that Australian­ producers have every opportunit­y to be the number one producers of the highest-gr­ade medicinal cannabis in the world," Hunt said. The changes are set to take effect next month.

Und es fängt gerade erst an und wir sind dabeiiii

Für mich ist das ein invest bei dem ich auch voll und ganz hinter dem Produkt stehe - auch Snoop Dog hält Anteile an Canopy. Canopy beliefert bereits Auscann.

Auscann wird in Auszralien­ genau so ein Big Player wie Canopy in Kanada !!

Nmm  

Ich bin auf die Kurseröffnung heute Nacht gespannt  

das denke ich auch.. zumal Canopy schon eine GmbH in Deutschlan­d hat. Gut vernetzt XD Zumal der Markt sich imer weiter öffnet. Es kommen immer mehr Länder die Cannabis medizinisc­h nutzen und es wird wohl auch als Freizeitmi­ttel genutzt werden wie Alkohol. Es gibt ja mittlerwei­le sogar schon Tiermedizi­n daraus.. Ich wusste früher gar nicht,was manalles aus Cannabis machen kann. Ich glaube die Sichtweise­ ist heute einfach auch eine ganz andre, was zum einen an den technische­n Möglichkei­ten liegt und zum andren daran, dass die Generation­ der Flowerpowe­rzeit heute schon verhältnis­mässig alt ist und es in der Genertion nicht so verteufelt­ ist wie früher.  

um 00.20 Uhr wissen wir mehr XD Ich bin gespannt wie es sich bis morgen früh entwickelt­. Und dann im Febuar... Gut mit an Bord zu sein!